

THE DEPARTMENT AND THE STATE BOARD OF PHARMACY SHALL REGULATE THE MANUFACTURE, DISTRIBUTION, AND SALE OF AMYGDALIN FOR USE IN THIS STATE, BUT ONLY TO ENSURE THAT THE AMYGDALIN IS NOT ADULTERATED, CONTAMINATED BY MICROORGANISMS, OR MISBRANDED.

REVISOR'S NOTE: This section is new language derived without substantive change from former Article 43, § 133(d) and (e).

Defined terms: "Department" § 1-101
"Physician" § 1-101

18-303. DIETHYLSTILBESTROL.

(A) PUBLIC INFORMATION CAMPAIGN.

(1) THE SECRETARY SHALL ESTABLISH AND PROMOTE A STATEWIDE PUBLIC INFORMATION CAMPAIGN ON DIETHYLSTILBESTROL (DES).

(2) THE PUBLIC INFORMATION CAMPAIGN SHALL:

(I) TRY TO REACH EACH INDIVIDUAL WHO HAS BEEN EXPOSED TO DIETHYLSTILBESTROL AND EACH OFFSPRING OF THOSE INDIVIDUALS, TO ENCOURAGE THE INDIVIDUALS AND OFFSPRING TO SEEK MEDICAL CARE FOR THE PREVENTION OR TREATMENT OF CANCER THAT RESULTS FROM THE EXPOSURE TO DIETHYLSTILBESTROL; AND

(II) INCLUDE ANY OTHER MATTER THAT THE SECRETARY CONSIDERS APPROPRIATE.

(B) SCREENING PROGRAM.

THE SECRETARY SHALL EXPAND EXISTING CANCER SCREENING PROGRAMS TO DETECT ANY CANCER OR OTHER ABNORMAL CONDITION THAT RESULTS FROM EXPOSURE TO DIETHYLSTILBESTROL, INCLUDING BREAST, CERVICAL, TESTICULAR, OR VAGINAL CANCER OR VAGINAL ADENOSIS.

(C) TRAINING PROGRAMS.

THE SECRETARY SHALL ESTABLISH A PROGRAM TO TRAIN PHYSICIANS, ~~PHYSICIAN~~ PHYSICIAN'S ASSISTANTS, AND NURSES IN:

(1) IDENTIFYING INDIVIDUALS WHO HAVE BEEN EXPOSED TO DIETHYLSTILBESTROL;

(2) DIAGNOSING AND TREATING ANY CANCER OR OTHER ABNORMAL CONDITION THAT RESULTS FROM THE EXPOSURE; AND

(3) PREVENTING EXPOSURE TO DIETHYLSTILBESTROL.